Inactive Instrument

Amarantus BioSciences Inc Stock price OTC Bulletin Board

Equities

US02300Q1058

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- USD 0.00% Intraday chart for Amarantus BioSciences Inc
Sales 2014 - Sales 2015 - Capitalization 8.57M
Net income 2014 -27M Net income 2015 -25M EV / Sales 2014 -
Net cash position 2014 89K Net Debt 2015 2.96M EV / Sales 2015 -
P/E ratio 2014
-2.06 x
P/E ratio 2015
-0.15 x
Employees -
Yield 2014 *
-
Yield 2015
-
Free-Float 100%
More Fundamentals * Assessed data
Sector Update: Financial Stocks Still Adding to Wednesday Declines MT
Todos Medical Ltd. (OTCPK:TOMD.F) completed the acquisition of remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc. CI
Amarantus BioScience Holdings, Inc. acquired majority interest in Hempori, Inc. for $0.38 million. CI
Amarantus Completes Sublicense of ESS, MANF and Phenoguard to Emerald Organic Products CI
Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary Manf Therapeutics CI
Amarantus Bioscience Holdings, Inc. Enters into Agreement to License Diverse Therapeutics Portfolio to CBD-Focused Emerald Organic Products with Emerald Organic Growth, Inc CI
Coeptis Pharmaceuticals, Inc. terminated the acquisition of Elto Pharma, Inc. from PsychoGenics Inc. and Amarantus BioScience Holdings, Inc.. CI
Amarantus Enters into Letter of Intent with the Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking Cessation CI
Amarantus BioScience Holdings, Inc. Announces Positive Pre-Clinical Data for Manf in Wolfram Syndrome CI
Amarantus Hires Evolution Venture Partners To Evaluate Alternatives For Expansion Into Legal Hemp CI
Todos Medical Ltd. (OTCPK:TOMD.F) exercised the option to acquire the remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc.. CI
Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries CI
Todos Medical Ltd. Enters into Joint Venture Agreement with Amarantus to Develop Alzheimer’S Blood Diagnostic Lympro Test 2.0 CI
Coeptis Pharmaceuticals, Inc. entered into a binding agreement to acquire Elto Pharma, Inc. from PsychoGenics Inc. and Amarantus BioScience Holdings, Inc.. CI
Amarantus Enters into Exclusive Option Agreement with Leipzig University to License IP Covering Alzheimer's Blood Diagnostic LymPro Test 2.0 Blood Test Vs. Amyloid Pet CI
More news
Managers TitleAgeSince
Founder 79 08-01-13
Founder 41 08-01-13
Chief Executive Officer 77 14-07-21
Members of the board TitleAgeSince
Chief Executive Officer 77 14-07-21
Founder 79 08-01-13
Founder 41 08-01-13
More insiders
Amarantus Bioscience Holdings, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The Company owns or has licenses to various product candidates in the biopharmaceutical healthcare industry. It has acquired the rights to the engineered skin substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by Company’s wholly owned subsidiary Cutanogen Corporation. The Company’s wholly owned subsidiary MANF Therapeutics, Inc. owns intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics, Inc. is developing MANF-based products as treatments for ophthalmological disorders.
More about the company
  1. Stock
  2. Equities
  3. Stock Amarantus BioScience Holdings, Inc.
  4. Stock Amarantus BioSciences Inc - OTC Bulletin Board